Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00850785 · ClinicalTrials.gov registry record · Phase 1
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00850785 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 6 participants.
The verdict
NCT00850785, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease. The primary objective of this trial is to evaluate immune responses induced by autologous DRibble vaccine in vivo and in vitro and against autologous and allogeneic lung cancer cells.
Interventions
- BIOLOGICAL DRibble vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00850785
The ClinicalTrials.gov registry entry for NCT00850785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DRibble vaccine is the first listed.
NCT00850785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00850785 about?
NCT00850785 is a clinical study titled "Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer". This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease. The primary objective of this trial is to evaluate immune responses induced by autologous DRibble vaccine in vivo and ...
What is the current status of trial NCT00850785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00850785?
The interventions under investigation include: DRibble vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00850785?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.